Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (3071)	12/2/1997 1:52:00 PM
From: Steve Fancy	Respond to of 6136

Agouron (NASDAQ:AGPH) falls on Roche (ZSE:ROCZ.G) exit Reuters, Tuesday, December 02, 1997 at 12:35 LOS ANGELES, Dec 2 (Reuters) - Shares of Agouron Pharmaceuticals Inc fell sharply Tuesday after the company said it would end development of one of its cancer drugs and drop all cancer drug collaboration with Hoffmann La-Roche. Analysts said the drop reflected not just the termination of the one cancer drug project, but the extra costs the company would have to take on as a result as losing Hoffmann La-Roche as a partner. They also voiced concern Agouron's popular AIDS drug, Viracept, would be hit hard by competition in 1998. Agouron shares were down 7-1/8 to 32-3/8. Agouron said it would discontinue development of its anti-cancer drug AG337, or Thymitaq, an agent designed to control tumor growth in head, neck and liver cancer. The company said it will continue developing other cancer drugs, such as AG3340, which inhibits the enzymes that help tumors metastasize. While the decision to exit the Thymitaq program was not a big surprise to those who had followed results of its clinical trials, the loss of Roche as a partner in all cancer projects stirred concern for two reasons. Mehta and Isaly analyst Michael Sheffery said it cast some doubt on the promise of these drugs even though it was still early in the development process. And, he said, it would force Agouron to pay research and development expenses on its own. Sheffery estimated this would push Agouron's R&D expenses up 20 percent in fiscal 1998, ending in June. An Agouron spokeswoman said the termination of the deal with Roche would not inhibit its work on other cancer drugs. She said the loss of Roche would have a "nominal negative impact" of less than $2 million in fiscal 1998. She said it would increase fiscal 1999 spending about 10 percent. Copyright 1997, Reuters News Service

To: tommysdad who wrote (3071)	12/2/1997 1:58:00 PM
From: Steve Fancy	Read Replies (3) \| Respond to of 6136

Man, the bad news keeps coming. Increased R & d expenses, doubts about the cancer drugs due to Roche backing out, and now even concerns about Viracept being hit hard by competition in '98. We are definetly back to the one-drug company debate. To further compound problems, I understand another newswire will be coming across with an analyst stating that AGPH is overvalued as a single drug company. A short field day. PW seems to feel the bottom will be around 29, give or take a point or two. sf sf